Key Points
- Elvia Cowan, Vaxcyte's CAO, sold 1,892 shares on March 17 at an average price of $55.57 for $105,138.44, reducing her ownership by 6.13% to 28,975 shares (about $1.61M), after prior sales on March 11 and December 23.
- Vaxcyte reported a Q4 EPS loss of ($1.80), missing estimates, yet analysts remain mostly bullish—the stock carries an average "Moderate Buy" rating with a $94.50 target—even as it trades around $54 with a market cap near $7.77 billion.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CAO Elvia Cowan sold 1,892 shares of the company's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $55.57, for a total value of $105,138.44. Following the completion of the sale, the chief accounting officer directly owned 28,975 shares in the company, valued at approximately $1,610,140.75. The trade was a 6.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Elvia Cowan also recently made the following trade(s):
- On Wednesday, March 11th, Elvia Cowan sold 2,500 shares of Vaxcyte stock. The stock was sold at an average price of $58.59, for a total value of $146,475.00.
- On Tuesday, December 23rd, Elvia Cowan sold 11,623 shares of Vaxcyte stock. The shares were sold at an average price of $47.92, for a total value of $556,974.16.
Vaxcyte Trading Down 0.5%
Vaxcyte stock traded down $0.26 on Thursday, hitting $54.02. 18,375 shares of the stock traded hands, compared to its average volume of 1,346,360. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $76.61. The firm has a market cap of $7.77 billion, a P/E ratio of -9.65 and a beta of 1.31. The business's fifty day simple moving average is $54.65 and its 200 day simple moving average is $46.42.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported ($1.80) earnings per share for the quarter, missing analysts' consensus estimates of ($1.46) by ($0.34). During the same period in the previous year, the firm earned ($1.12) EPS. As a group, analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.
Institutional Investors Weigh In On Vaxcyte
Large investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its position in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company's stock worth $27,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company's stock valued at $30,000 after acquiring an additional 600 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company's stock valued at $34,000 after acquiring an additional 184 shares during the last quarter. Allworth Financial LP grew its stake in shares of Vaxcyte by 148.9% in the third quarter. Allworth Financial LP now owns 1,222 shares of the company's stock worth $44,000 after acquiring an additional 731 shares during the period. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Vaxcyte in the third quarter worth approximately $45,000. 96.78% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of brokerages have weighed in on PCVX. BTIG Research raised their target price on shares of Vaxcyte from $85.00 to $89.00 and gave the company a "buy" rating in a research note on Wednesday, February 25th. Jefferies Financial Group restated a "buy" rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a research report on Friday, January 9th. Needham & Company LLC lifted their price objective on Vaxcyte from $90.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Finally, Guggenheim reissued a "buy" rating and issued a $116.00 target price on shares of Vaxcyte in a research note on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $94.50.
View Our Latest Stock Report on PCVX
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
